Pharmaceutical - Markets & Marketing, Japan

Filter

Current filters:

Markets & MarketingJapan

Popular Filters

Acute coronary syndrome treatment market to more than triple by 2023

Acute coronary syndrome treatment market to more than triple by 2023

30-07-2014

The launch of several drugs with “extraordinary blockbuster potential” will cause the acute coronary…

Acute coronary syndromealirocumabAmgenBayerCardio-vascularEuropeevolocumabJapanMarkets & MarketingMerck & CoPfizerPharmaceuticalSanofiUSAXareltoZontivity

Drug-treated hepatitis C population to more than double by 2016

Drug-treated hepatitis C population to more than double by 2016

16-07-2014

The hepatitis C virus population is already large, with 2 million diagnosed, chronically infected cases…

Anti-viralsCytokinesDaklinzaDecision Resources GroupEuropeHepatitis CInterferonJapanMarkets & MarketingPharmaceuticalUSA

Rilutek patent expiry to cause negative growth in ALS treatment market by 2018

Rilutek patent expiry to cause negative growth in ALS treatment market by 2018

25-06-2014

The amyotrophic lateral sclerosis (ALS) treatment market value will decline from $64 million in 2013…

EuropeJapanMarkets & MarketingNeurologicalPatentsPharmaceuticalRilutekSanofiUSA

Third-party investigation confirms Takeda’s systematic involvement in CASE-J Study, but no data tampering

Third-party investigation confirms Takeda’s systematic involvement in CASE-J Study, but no data tampering

23-06-2014

Japan’s largest drugmaker Takeda Pharmaceuticals has updated on the third-party surrounding the results…

BlopressCardio-vascularJapanMarkets & MarketingPharmaceuticalResearchTakeda Pharmaceutical

Takelda combination tablets now available in Japan

Takelda combination tablets now available in Japan

13-06-2014

Japan’s largest drugmaker Takeda Pharmaceutical says that Takelda, a fixed-dose combination (FDC) of…

Gastro-intestinalsJapanMarkets & MarketingPharmaceuticalTakeda PharmaceuticalTakelda

Daiichi Sankyo launches blood thinner Efient in Japan

27-05-2014

Daiichi Sankyo said this morning that it has launched its anti-blood clotting drug Efient (prasugrel…

Cardio-vascularDaiichi SankyoEfientJapanMarkets & MarketingPharmaceuticalRegulation

JPMA sanctions against Takeda over promotional activities for candesartan in Japan

09-04-2014

Japan’s largest drugmaker Takeda Pharmaceutical says it has received notice of sanctions imposed by…

Asia-PacificBlopressCardio-vascularJapanMarkets & MarketingPharmaceuticalTakeda Pharmaceuticals

Otsuka and Takeda to co-promote TAK-438 in the GI therapy area in Japan

Otsuka and Takeda to co-promote TAK-438 in the GI therapy area in Japan

29-03-2014

Japanese drugmakers Otsuka Pharmaceutical and Takeda Pharmaceutical have entered into a co-promotion…

Asia-PacificGastro-intestinalsJapanLicensingMarkets & MarketingOtsukaPharmaceuticalTAK-438Takeda Pharmaceuticalsvonoprazan

Asia-Pacific NSCLC market to reach $2.9 billion by 2019

Asia-Pacific NSCLC market to reach $2.9 billion by 2019

18-03-2014

The non-small cell lung cancer (NSCLC) therapeutics market value in the Asia-Pacific (APAC) region -…

Asia-PacificAustraliaChinaIndiaJapanMarkets & MarketingOncologyPharmaceutical

Japan’s market for schizophrenia treatment to double by 2022

Japan’s market for schizophrenia treatment to double by 2022

12-03-2014

Japan’s schizophrenia treatment market value will undergo significant growth over the coming decade,…

Asia-PacificJapanMarkets & MarketingNeurologicalPharmaceutical

Takeda re-aligns marketing system in Japan

24-02-2014

Japan’s largest drugmaker Takeda Pharmaceutical says it decided to re-align its marketing system in…

Asia-PacificJapanManagementMarkets & MarketingPharmaceuticalTakeda Pharmaceuticals

Company Spotlight

ImmunoGen

ImmunoGen

Back to top